QIAGEN Digital Insights’ Post

🔥 Have burning questions for the curators behind COSMIC Actionability? Here's your chance to get answers!   Join us on March 7 for an exclusive webinar featuring a live Q&A session with Dr. Steve Jupe, COSMIC Actionability's principal curator. Led by Dr. Kyle Nilson, this webinar will explore a series of use cases demonstrating how #cancer and #biopharma labs can harness COSMIC (Catalogue of Somatic Mutations in Cancer) to: ☑️ Evaluate genomic loci using COSMIC’s comprehensive coding and non-coding variant annotations ☑️ Integrate variants with curated findings and summaries of mutational impact and clinical actionability ☑️ Use mutational signatures for potential clinical diagnosis and drug development applications   Don't miss out! Register now ⬇️ #drugdevelopment #precisiononcology

The fullerenol−doxorubicin conjugate suppressed the proliferation of cancer cell-lines in vitro through a G2-M cell cycle block, resulting in apoptosis. Furthermore, in an in vivo murine tumor model, fullerenol−doxorubicin exhibited comparable antitumor efficacy as free drug without the systemic toxicity of free doxorubicin. Additionally, we demonstrate that the fullerenol platform can be extended to other chemotherapeutic agents, such as the slightly water-soluble cisplatin, and can emerge as a new paradigm in the management of cancer.

📢 Excited to share our new study w/Genentech on how #offlabel drugs are used in 165K #cancer patients https://lnkd.in/gsgaeSrk Takeaways👇: *19% of patients receive off-label cancer drugs (4% for off-guideline); tend to be younger or at academic sites *we IDed mutations predicting treatment outcome *immunotherapies often used before FDA approval *we also built a #transformer to predict when patients receive off-guideline treatments. Much more in our paper! #realworldevidence #cancertreatment #machinelearning Fantastic job by Ruishan Liu, Lisa Wang, Shemra Rizzo, Navdeep Pal, Marius Garmhausen, Sarah Waliany, Sarah McGough, PhD, Yvonne Lin, Zhi Huang, Joel Neal and Ryan Copping 👏👏

Adjuvant therapy and combination therapy leverage the strengths of different treatments to provide a more robust and comprehensive approach to cancer care. By targeting multiple pathways, reducing resistance, lowering dosages, and addressing tumor heterogeneity, these strategies offer improved efficacy and outcomes compared to mono-therapy. Below is an example!

Transcriptional coactivators CBP/p300 have emerged as potential targets for cancer therapeutics. This Viewpoint discusses recent results that demonstrate an exceptionally potent and orally efficacious CBP/p300 degrader for the treatment of prostate cancer. This degrader stands out as a promising new candidate for cancer therapy and deserves further research. https://lnkd.in/ge4KzpS5 |#drugdevelopment #science #medicinalchemistry #drugdiscovery #medicine #drugspharmaceuticals #oncology #drug

What are the benefits of advanced cancer treatments compared to traditional therapies? Advanced cancer treatments offer several benefits: Enhanced Effectiveness: Targeted therapies and immunotherapies are often more effective and precise, resulting in better outcomes and fewer side effects. Personalized Approach: Advanced treatments are often tailored to an individual’s genetic and molecular profile, maximizing effectiveness while minimizing unnecessary treatment. Reduced Side Effects: Compared to traditional chemotherapy and radiation, advanced therapies can have fewer severe side effects, improving quality of life during treatment. Increased Survival Rates: Many advanced treatments have shown to significantly improve survival rates and long-term outcomes, especially in cases of advanced or metastatic cancer. #advanced_cancer_treatment

THERANOSTICS: RESURGENCE IN CANCER CHEMOTHERAPY? Theranostics is a class of medicine that can be used both for diagnostics and treatment. https://lnkd.in/gp7pNEXM In cancer, there is a renewed interest in development of theranostics. A recently approved theranostic by the FDA for treatment of cancer is Pluvicto (177Lu-PSMA-617), for metastatic prostate cancer, a drug which generated 1 billion USD. Now there is a rush by major Pharma to acquire radiopharmaceutical companies. This video beautifully explains how theranostics work.

If you missed our webinar, A New Frontier in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Biomarker Testing, you can view it with the link below. The webinar explores the role cfHPV-DNA plays in cancer prognosis, and what barriers biopharma companies face in incorporating cfHPV-DNA into their clinical trial design. The speakers discuss how pharma manufacturers, HCPs and patients can collaborate to help overcome these barriers. #HPV #CancerResearch https://hubs.la/Q02kBkYH0

Regulating #ferroptosis to treat #cancer is at the heart of what we are striving to achieve for patients. We are developing next-generation small-molecule medicines to block key molecular targets in the ferroptosis-inducing pathways. At Kojin Therapeutics, our focus is on common and rare cancers that are highly susceptible to ferroptosis #celldeath mechanisms. Join us in celebrating the importance of innovative cancer research on 2024 #worldcancerresearchday. Together, we can increase awareness of the importance of advances in new therapeutic strategies that may increase survival and reduce the global burden of cancer. #drugdiscovery #redox #biotech #chemicalbiology #glutathione

Why are Antibody Drug Conjugates (ADCs) so important for cancer patients? Michelle Morand, Precision Cancer Advocacy Specialist, explains how a new type of cancer treatment – called Antibody Drug Conjugates (ADCs) – are helping cancer patients have great success, even for those with late stage or rare cancers. https://lnkd.in/gXRFmGdN Join our new free online advocacy program, Cancer: Just the Facts  https://lnkd.in/gd9pMpNd And get all your cancer care questions answered, by experts. #CancerJustTheFacts